MorphoSys (ETR:MOR) has been assigned a €85.00 ($101.19) price objective by Berenberg Bank in a note issued to investors on Thursday, December 7th. The firm presently has a “buy” rating on the stock. Berenberg Bank’s target price suggests a potential upside of 9.68% from the stock’s previous close.
Several other equities analysts also recently issued reports on MOR. Independent Research set a €93.00 ($110.71) price objective on MorphoSys and gave the company a “buy” rating in a research report on Friday, December 1st. Goldman Sachs Group set a €80.00 ($95.24) price objective on MorphoSys and gave the company a “neutral” rating in a research report on Monday, November 27th. Deutsche Bank set a €90.00 ($107.14) target price on MorphoSys and gave the stock a “buy” rating in a research report on Wednesday, November 8th. Oddo Bhf set a €90.00 ($107.14) target price on MorphoSys and gave the stock a “buy” rating in a research report on Wednesday, November 8th. Finally, JPMorgan Chase & Co. set a €85.00 ($101.19) price objective on MorphoSys and gave the stock a “buy” rating in a research note on Wednesday, November 8th. Two analysts have rated the stock with a hold rating and six have given a buy rating to the company’s stock. The stock has an average rating of “Buy” and a consensus price target of €83.75 ($99.70).
MorphoSys (ETR MOR) traded up €0.92 ($1.10) during trading on Thursday, hitting €77.50 ($92.26). The company had a trading volume of 91,410 shares, compared to its average volume of 135,907. The company has a market cap of $2,250.00 and a P/E ratio of -26.27. MorphoSys has a 1-year low of €46.50 ($55.36) and a 1-year high of €83.83 ($99.80).
ILLEGAL ACTIVITY WARNING: This news story was reported by TrueBlueTribune and is the property of of TrueBlueTribune. If you are accessing this news story on another publication, it was illegally copied and republished in violation of United States and international trademark and copyright laws. The legal version of this news story can be viewed at https://www.truebluetribune.com/2018/01/02/morphosys-mor-pt-set-at-85-00-by-berenberg-bank.html.
MorphoSys Company Profile
MorphoSys AG, together with its subsidiaries, engages in the research, development, and optimization of therapeutic antibody drug candidates in partnerships with pharmaceutical and biotechnology companies. The company, together with its pharmaceutical partners, develops a therapeutic pipeline of approximately 100 human antibody drug candidates for the treatment of cancer, rheumatoid arthritis, Alzheimer's disease, infectious diseases, cardiovascular dysfunction, and inflammation.
Receive News & Ratings for MorphoSys Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for MorphoSys and related companies with MarketBeat.com's FREE daily email newsletter.